<DOC>
	<DOCNO>NCT00021047</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine epirubicin , carboplatin , capecitabine treat patient unresectable locally advanced , metastatic , recurrent solid tumor .</brief_summary>
	<brief_title>Epirubicin , Carboplatin , Capecitabine Treating Patients With Unresectable Locally Advanced , Metastatic , Recurrent Solid Tumor</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II dose capecitabine administer epirubicin carboplatin patient unresectable locally advanced , metastatic , recurrent solid tumor . - Determine toxic effect regimen patient . - Determine pharmacokinetics ( PK ) capecitabine correlate PK parameter clinical toxicity regimen patient . - Correlate end-of-infusion level epirubicin metabolite epirubicin dose clinical toxicity regimen patient . - Determine possible correlation polymorphism promoter region thymidylate synthase gene clinical toxicity regimen patient . - Determine antitumor activity regimen patient . OUTLINE : This dose-escalation study capecitabine . Patients receive epirubicin IV 2 hour carboplatin IV 30 minute day 1 oral capecitabine twice daily day 2-5 , 8-12 , 15-19 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 24 additional patient treat recommended phase II dose . PROJECTED ACCRUAL : A total 3-45 patient ( 24 patient phase II ) accrue study within 2 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor Progressive disease standard therapy , include : Locally advance , unresectable primary recurrent tumor OR Metastatic disease Previously untreated metastatic cancer study regimen represent reasonable initial chemotherapy palliative intent ( e.g. , metastatic gastric cancer , hepatobiliary cancer , cancer effective standard therapy exists ) allow Phase II portion : Diagnosis cancer upper aerodigestive tract ( head neck , esophagus , stomach , hepatobiliary ) No potential curative treatment option include surgery , radiotherapy , chemoradiotherapy , combination chemotherapy No leukemia lymphoma No primary CNS malignancy CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST ALT great 2.5 time upper limit normal Renal : Creatinine great 1.6 mg/dL Cardiovascular : LVEF least 50 % No symptomatic congestive heart failure No unstable angina No cardiac arrhythmia Other : No serious concurrent medical illness would preclude study participation No active infection require IV antibiotic therapy No history allergy platinum compound , mannitol , antiemetic use study drug No history severe intolerance fluorouracil Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : More 4 week since prior immunotherapy recover Chemotherapy : See Disease Characteristics More 4 week since prior chemotherapy ( least 6 week nitrosoureas mitomycin ) recover No prior cumulative doxorubicin dose 300 mg/m2 Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy recover At least 8 week since prior strontium chloride Sr 89 Surgery : See Disease Characteristics Recovered prior surgery Other : At least 4 week since prior sorivudine brivudine No concurrent sorivudine brivudine No concurrent cimetidine No concurrent antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
</DOC>